Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain

Other authors

Institut Català de la Salut

[Fuentes A, Serrano-Conde E] Hospital Universitario Clínico San Cecilio, Instituto de Investigación Ibs, Av, Innovación S/N, 18016 Granada, Spain. [Roldán C] Complejo Hospitalario de Jaén, Jaén, Spain. [Benito-Ruesca R] Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Mejías G] Hospital Universitario de Burgos, Burgos, Spain. [Sampedro A] Hospital Universitario Virgen de las Nieves, Granada, Spain. [Esperalba J] Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-06-23T11:39:54Z

2021-06-23T11:39:54Z

2021-06



Abstract

Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Diagnòstic; IgA


Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Diagnóstico; IgA


Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Diagnosis; IgA


Aim To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. Methods IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used. Results Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively. Conclusion The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.


The ELISA kits for the IgG and IgM + IgA assays were provided by Vircell SL. No additional funding was received.

Document Type

Article


Published version

Language

English

Publisher

Springer

Related items

European Journal of Clinical Microbiology & Infectious Diseases;40

https://link.springer.com/article/10.1007/s10096-020-04139-5

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)